The US anal fistula drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). A tunnel or tract between the epithelial surface of the rectum or anus and the skin, which is the perianal area, is known as an anal fistula. Infection of this tract can result in edema, pus, and pain. A huge patient pool has resulted from the high incidence rate of anal fistula. Furthermore, an increase in the incidence of anal fistula-inducing co-morbidities such as Crohn's disease, anal abscess, HIV, and tuberculosis infections has led to an increase in the number of complex anal fistula cases. The high prevalence of inflammatory bowel illnesses (IBD) such as Crohn's disease and ulcerative colitis is also contributing to the growth of the market in the country.
According to the data released by the UCLA Center for IBD, in February 2019, around 1.6 million Americans were suffering from IBD and growing around 70,000 new cases each year. The people diagnosed majorly fell in the age group of 15-30 years. As per the study released by the American College of Gastroenterology, in 2019, around 10% - 15% out of the total adult population are suffering from IBS in the US. However, only 5% -7% have been diagnosed with IBS diseases among the adult population of the country. This, in turn, is driving the demand for anal fistula drugs such as laxatives, antibiotics, and calcium channel blockers, among others.
Market Coverage
Competitive Landscape: Takeda Pharmaceutical Co. Ltd., and Pfizer Inc., among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
United States Anal Fistula Drugs Market Report by Segment
By Type
• Laxatives
• Antibiotics
• Calcium Channel Blockers
• OnabotulinumtoxinA Injections
• Topical Nitrates
• Others
United States Anal Fistula Drugs Market by Region
North America
Europe
Asia-Pacific
Rest of the World